|
|
| (22 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT[[Rifapentine]] |
| |authorTag={{KS}}
| |
| |genericName=rifapentine
| |
| |aOrAn=an
| |
| |drugClass=antimycobacterial drug
| |
| |indicationType=treatment
| |
| |indication=active [[pulmonary tuberculosis]] and [[latent tuberculosis]]
| |
| |adverseReactions=[[anemia]], [[lymphopenia]], [[neutropenia]], increased ALT, [[arthralgia]], [[conjunctivitis]], [[headache]], [[vomiting]], [[nausea]], [[diarrhea]], [[rash]], [[pruritus]], [[anorexia]] and [[lymphadenopathy]]
| |
| |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
| |
| | |
| * Content
| |
| | |
| <!--Adult Indications and Dosage-->
| |
| | |
| <!--FDA-Labeled Indications and Dosage (Adult)-->
| |
| |fdaLIADAdult===Indications==
| |
| | |
| '''Active Pulmonary Tuberculosis'''
| |
| | |
| * PRIFTIN® (rifapentine) is indicated in adults and children 12 years and older for the treatment of active [[pulmonary tuberculosis]] ([[TB]]) caused by [[Mycobacterium tuberculosis]]. PRIFTIN must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible.
| |
| | |
| '''Limitations of Use'''
| |
| | |
| * Do not use PRIFTIN monotherapy in either the initial or the continuation phases of active antituberculous treatment.
| |
| | |
| * PRIFTIN should not be used once-weekly in the continuation phase regimen in combination with isoniazid (INH) in HIV-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin (RIF)-resistant organisms.
| |
| | |
| * PRIFTIN has not been studied as part of the initial phase treatment regimen in HIV- infected patients with active pulmonary tuberculosis.
| |
| | |
| '''Latent Tuberculosis Infection'''
| |
| | |
| * PRIFTIN is indicated in adults and children 2 years and older for the treatment of latent tuberculosis infection caused by Mycobacterium tuberculosis in patients at high risk of progression to tuberculosis disease (including those in close contact with active tuberculosis patients, recent conversion to a positive tuberculin skin test, HIV-infected patients, or those with pulmonary fibrosis on radiograph).
| |
| | |
| '''Limitations of Use'''
| |
| | |
| * Active tuberculosis disease should be ruled out before initiating treatment for latent tuberculosis infection.
| |
| | |
| * PRIFTIN must always be used in combination with isoniazid as a 12-week once-weekly regimen for the treatment of latent tuberculosis infection.
| |
| | |
| * PRIFTIN in combination with isoniazid is not recommended for Individuals presumed to be exposed to rifamycin- or - isoniazid resistant M. tuberculosis.
| |
| | |
| ==Dosage==
| |
| | |
| '''Dosage in Active Pulmonary Tuberculosis'''
| |
| | |
| * PRIFTIN is only recommended for the treatment of active pulmonary tuberculosis caused by drug-susceptible organisms as part of regimens consisting of a 2 month initial phase followed by a 4 month continuation phase.
| |
| | |
| * PRIFTIN should not be used in the treatment of active pulmonary tuberculosis caused by rifampin-resistant strains.
| |
| | |
| * '''Initial phase (2 Months)''': PRIFTIN should be administered at a dose of 600 mg twice weekly for two months as directly observed therapy (DOT), with an interval of no less than 3 consecutive days (72 hours) between doses, in combination with other anti- tuberculosis drugs as part of an appropriate regimen which includes daily companion drugs such as isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA).
| |
| | |
| * '''Continuation phase (4 Months)''': Following the initial phase (2 months), continuation phase (4 months) treatment consists of PRIFTIN 600 mg once-weekly for 4 months in combination with isoniazid or another appropriate anti- tuberculosis agent for susceptible organisms administered as directly observed therapy.
| |
| | |
| '''Dosage in Latent Tuberculosis Infection'''
| |
| | |
| * PRIFTIN should be administered once-weekly in combination with isoniazid for 12 weeks as directly observed therapy.
| |
| | |
| * '''Adults and children 12 years and older''': The recommended dose of PRIFTIN should be determined based on weight of the patient up to a maximum of 900 mg once-weekly (see TABLE 1). The recommended dose of isoniazid is 15 mg/kg (rounded to the nearest 50 mg or 100mg) up to a maximum of 900 mg once-weekly for 12 weeks.
| |
| | |
| * '''Children 2–11 years''': The recommended dose of PRIFTIN should be determined based on weight of the patient up to a maximum of 900 mg once- weekly (see TABLE 1). The recommended dose of isoniazid is 25 mg/kg (rounded to the nearest 50 mg or 100mg) up to a maximum of 900 mg once-weekly for 12 weeks.
| |
| | |
| [[File:XXXXX.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
| |
| | |
| ==DOSAGE FORMS AND STRENGTHS==
| |
| | |
| * PRIFTIN is supplied as 150 mg round normal convex dark-pink film-coated tablets debossed "Priftin" on top and "150" on the bottom.
| |
| | |
| |offLabelAdultGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
| | |
| | |
| |offLabelAdultNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
| |
| | |
| | |
| |fdaLIADPed=* There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
| |
| | |
| | |
| | |
| <!--Guideline-Supported Use (Pediatric)-->
| |
| |offLabelPedGuideSupport=* There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
| | |
| | |
| |offLabelPedNoGuideSupport=* There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
| |
| | |
| | |
| |contraindications='''Hypersensitivity'''
| |
| | |
| * PRIFTIN is contraindicated in patients with a history of [[hypersensitivity]] to rifamycins.
| |
| |clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
| |
| | |
| =====Body as a Whole=====
| |
| | |
| | |
| | |
| | |
| =====Cardiovascular=====
| |
| | |
| | |
| | |
| | |
| =====Digestive=====
| |
| | |
| | |
| | |
| | |
| =====Endocrine=====
| |
| | |
| | |
| | |
| | |
| =====Hematologic and Lymphatic=====
| |
| | |
| | |
| | |
| | |
| =====Metabolic and Nutritional=====
| |
| | |
| | |
| | |
| | |
| =====Musculoskeletal=====
| |
| | |
| | |
| | |
| | |
| =====Neurologic=====
| |
| | |
| | |
| | |
| | |
| =====Respiratory=====
| |
| | |
| | |
| | |
| | |
| =====Skin and Hypersensitivy Reactions=====
| |
| | |
| | |
| | |
| | |
| =====Special Senses=====
| |
| | |
| | |
| | |
| | |
| =====Urogenital=====
| |
| | |
| | |
| | |
| | |
| =====Miscellaneous=====
| |
| | |
| | |
| | |
| <!--Postmarketing Experience-->
| |
| |postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
| |
| | |
| =====Body as a Whole=====
| |
| | |
| | |
| | |
| =====Cardiovascular=====
| |
| | |
| | |
| | |
| =====Digestive=====
| |
| | |
| | |
| | |
| =====Endocrine=====
| |
| | |
| | |
| | |
| =====Hematologic and Lymphatic=====
| |
| | |
| | |
| | |
| =====Metabolic and Nutritional=====
| |
| | |
| | |
| | |
| =====Musculoskeletal=====
| |
| | |
| | |
| | |
| =====Neurologic=====
| |
| | |
| | |
| | |
| =====Respiratory=====
| |
| | |
| | |
| | |
| =====Skin and Hypersensitivy Reactions=====
| |
| | |
| | |
| | |
| =====Special Senses=====
| |
| | |
| | |
| | |
| =====Urogenital=====
| |
| | |
| | |
| | |
| =====Miscellaneous=====
| |
| | |
| | |
| | |
| <!--Drug Interactions-->
| |
| |drugInteractions=* Drug
| |
| :* Description
| |
| | |
| <!--Use in Specific Populations-->
| |
| |useInPregnancyFDA=* '''Pregnancy Category'''
| |
| |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
| |
| | |
| There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
| |
| |useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
| |
| |useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
| |
| |useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
| |
| |useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
| |
| |useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
| |
| |useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
| |
| |useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
| |
| |useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
| |
| |useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
| |
| |useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
| |
| | |
| <!--Administration and Monitoring-->
| |
| |administration=* Oral
| |
| | |
| * Take PRIFTIN with meals. Administration of PRIFTIN with a meal increases oral bioavailability and may reduce the incidence of gastrointestinal upset, nausea, and/or vomiting.
| |
| | |
| * For patients who cannot swallow tablets, the tablets may be crushed and added to a small amount of semi-solid food, all of which should be consumed immediately.
| |
| |monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label
| |
| |IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Overdosage-->
| |
| |overdose====Acute Overdose===
| |
| | |
| ====Signs and Symptoms====
| |
| | |
| * Description
| |
| | |
| ====Management====
| |
| | |
| * Description
| |
| | |
| ===Chronic Overdose===
| |
| | |
| There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Pharmacology-->
| |
| | |
| <!--Drug box 2-->
| |
| |drugBox=<!--Mechanism of Action-->
| |
| |mechAction=*
| |
| | |
| <!--Structure-->
| |
| |structure=*
| |
| | |
| : [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
| |
| | |
| <!--Pharmacodynamics-->
| |
| |PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Pharmacokinetics-->
| |
| |PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Nonclinical Toxicology-->
| |
| |nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Clinical Studies-->
| |
| |clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--How Supplied-->
| |
| |howSupplied=*
| |
| |packLabel=<!--Patient Counseling Information-->
| |
| |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
| |
| | |
| <!--Precautions with Alcohol-->
| |
| |alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| | |
| <!--Brand Names-->
| |
| |brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
| |
| | |
| <!--Look-Alike Drug Names-->
| |
| |lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref>
| |
| | |
| <!--Drug Shortage Status-->
| |
| |drugShortage=
| |
| }}
| |
| {{PillImage
| |
| |fileName=No image.jpg
| |
| }}
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png
| |
| }}
| |
| {{LabelImage
| |
| |fileName={{PAGENAME}}11.png
| |
| }}
| |
| <!--Pill Image-->
| |
| | |
| | |
| | |
| <!--Label Display Image-->
| |
| | |
| | |
| | |
| | |
| | |
| <!--Category-->
| |
| | |
| [[Category:Rifamycin antibiotics]]
| |
| [[Category: Drug]] | |